期刊文献+

HCMV pp65 DNA疫苗的纯化与检定

Purification and standardization of HCMV pp65 DNA vaccine
下载PDF
导出
摘要 目的研究HCMV pp65 DNA疫苗(pcDNA3.1-pp65)的纯化工艺,并建立质控标准。方法对工程菌(DH5α/pcDNA3.1-pp65)的高效发酵菌体采用碱裂解法进行质粒初提;三步柱层析(依次为分子筛层析、亲和层析、阴离子层析)对质粒进行纯化,检测质粒含量、超螺旋比例、内毒素等,最后对终产品质粒溶液进行全面质量检定。结果质粒初提液通过分子筛层析后,去除了大量RNA、宿主DNA、内毒素等,再经亲和柱纯化后获得了高比例的超螺旋质粒DNA,达95%,经阴离子柱层析有效去除内毒素,质粒得率为0.8-0.95 mg/g菌,质粒总回收率达72.7%。三批终产品全面质量检定均符合规定。结论建立了稳定的HCMV pp65 DNA疫苗(pcDNA3.1-pp65)纯化工艺及质量控制标准,为进一步研究奠定了重要基础。 Objective To develop a procedure of purification and a standard for quality control of HCMV pp65 DNA vaccine.Methods To extract plasmids from recombinant E.coli DH5 α/ pcDNA3.1-pp65 by alkaline Lysis respectively and purify by three steps of chromatography,i.e.molecular sieve,affinity and anion exchange chromatography.Control tests were performed on the purified plasmids.Results Most of foreign matters such as RNA,host DNA and endotoxin were removed from the crude extract of plasmids by molecular sieve chromatography.After affinity chromatography,the proportion of supercoiled plasmid DNA reached 95 %.After anion exchange chromatography,endotoxin was removed effectively,and the plasmids were concentrated.The yield and total recovery rate of plasmids reached 0.8~0.951 mg/ g bacteria and 72.7 % respectively.All the quality control indexes of three batches of final products of plasmids met the relevant requirements.Conclusion A stable procedure of purification as well as a standard for quality control of HCMV pp65 DNA vaccine were developed,which laid a foundation for further study.
出处 《安徽医学》 2010年第3期201-204,共4页 Anhui Medical Journal
基金 安徽省教育厅自然科学研究计划项目(编号:2004kj218) 安徽省科技攻关计划重大科技专项(编号:08010302179) 国家自然科学基金资助项目(项目批准号:30872253)
关键词 HCMV PP65 DNA疫苗 质粒 纯化 HCMV pp65 DNA vaccine Plasmid Purification
  • 相关文献

参考文献13

  • 1Hillyer CD, Snydman DR, Berkman EM. The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients : transfusion of blood products. Transfusion, 1990,30(7) : 659 -666.
  • 2Vogel JU, Scholz M, Cinatl J Jr. Treatment of cytomegalovirus diseases. Intervirology, 1997,40 ( 5 ) :357 - 367.
  • 3Schalich J, Vytvytska O, Zauner W, et al. Analysis of the human cytomegalovirus pp65 - directed T - cell response in healthy HLA - A2 - positive individuals. Biol Chem,2008, 389(5) :551 -559.
  • 4Kim EK, Cho HI, Yoon SH, et al. Efficient generation of survivin - specific cytotoxic T lymphocytes from healthy persons in vitro: quantitative and qualitative effects of CD4 + T cells. Vaccine,2008,26 (32) :3987 - 3997.
  • 5李艳秋,余莉,方草晖,张文艳,王明丽.HCMV pp65 DNA疫苗诱导小鼠的细胞免疫应答[J].安徽医科大学学报,2003,38(2):98-102. 被引量:7
  • 6US FDA. GuidelinelGuidance for human somatic cell therapy and gene therapylHum. Gene Ther, 1998,9 (10) : 1513 - 1524.
  • 7Solache A, Morgan CL, Dodi AI, et al. Identification of three HLA - A * 0201 - restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus . J Immunol, 1999,163 (10) : 5512 -5518.
  • 8Yang R, Xia T, Xu G, et al. Human cytomegalovirus specific CD8 ( + ) T lymphocytes display interferon - gamma secretion impairment in kidney transplant recipients with pp65 antigenemia. Transplant Proc ,2008,40(10) :3500-3504.
  • 9Cantisan S, Torre -Cisneros J, Lara R, et al. Age -dependent association between low frequency of CD27/CD28 expression on pp65 CD8 + T cells and cytomegalovirus replication after transplantation. Clin Vaccine Immunol,2009,16 (10) :1429 - 1438.
  • 10Ledwith B J, Manam S, Troilo P J, et al. Plasmid DNA vaccines : investigation of integration into host cellular DNA following intramuscular injection in micel. Intervirology,2000, 43 (426) :258 -272.

二级参考文献1

  • 1薛彬主编.免疫毒理学试验技术[M].北京:北京医科大学联合出版社,1995.19.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部